FDA Approves New EPM Treatment

IDEXX Laboratories, Inc. announced Nov. 19 that it received approval from the U.S. Food and Drug Administration (FDA) to market and sell Navigator (32% nitazoxanide) antiprotozoal oral paste, a new treatment for equine protozoal myeloencephalitis (EPM). EPM is a progressive, degenerative disease of the central nervous system that can cause serious or even fatal neurological problems in horses

To continue reading this article, become a member of TheHorse.com.

It's FREE and you'll get full access to more than 20,000 articles, video, free reports & more.

Sign In
Stay on top of the most recent Horse Health news with FREE weekly newsletters from TheHorse.com. Learn More

Free Newsletters

Sign up for the latest in:

From our partners